Strategic Priority 3: Driving Regulatory Reform & System Innovation

SCROLL DOWN

Goal

To lead efforts to modernize Canada’s regulatory landscape to enable faster access to pediatric rare disease therapies. By collaborating with Health Canada, policy makers, and global partners, we aim to reduce trial barriers, align policies with innovation, and integrate clinical trials as part of standard patient care. This is broken down into 3 key initiatives:

  1. Regulatory Pathways

  2. Global Engagement

  3. Access Pathways for Therapies Unfit for Commercialization

Scroll through below to find out more about these initiatives